# Evogene Ltd.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Evogene Ltd.).

## Overview

Evogene Ltd. is a computational chemistry company that uses generative AI to design small molecules for pharmaceutical and agricultural applications. The company is based in Israel and operates through its public listings in the United States and Israel, with technology developed around its ChemPass AI platform.

## Products & services

• ChemPass AI generative molecular design platform
• Small-molecule discovery for crop protection
• Small-molecule discovery for pharmaceutical uses
• AI-guided lead generation and optimization
• Research partnerships and product development collaborations

- **Generative AI chemistry platform** (20%) — Computational tools used to generate and optimize novel small molecules.
- **Agricultural discovery programs** (45%) — Crop-protection molecule programs and related ag-biological development work.
- **Pharmaceutical discovery programs** (25%) — Small-molecule programs and partner-enabled discovery work for pharma uses.
- **Collaborative research and licensing** (10%) — Partnership-based R&D services, milestones, and technology access arrangements.

- ChemPass AI generative molecular design platform
- Small-molecule discovery for crop protection
- Small-molecule discovery for pharmaceutical uses
- AI-guided lead generation and optimization
- Research partnerships and product development collaborations

## Customers

Evogene serves pharmaceutical and agricultural industry partners that need early-stage molecule discovery, optimization, and validation. Its buyers typically include companies seeking external innovation, access to AI-driven discovery tools, or differentiated crop-protection candidates. The business model depends on converting internal platform capability into partner programs and product opportunities.

- **Agricultural chemistry partners** (primary) — Buy crop-protection discovery programs and molecular design capabilities to source differentiated fungicides, herbicides, or other actives.
- **Pharmaceutical discovery partners** (secondary) — Buy AI-enabled small-molecule discovery and optimization services for therapeutic programs.
- **Strategic R&D collaborators** (secondary) — Partner on platform access, shared research, and milestone-based development programs.

- Agrochemical companies seeking new crop-protection molecules
- Pharmaceutical partners looking for small-molecule discovery support
- Innovation teams that outsource early-stage R&D risk
- Partners needing AI-based lead generation and optimization
- Commercial collaborators using platform-enabled discovery programs

## Geography

Evogene is headquartered in Israel and lists on both Nasdaq and the Tel Aviv Stock Exchange. Its business is global in orientation because agricultural and pharmaceutical discovery programs are typically partnered internationally, while the company’s research and corporate functions are centered in Israel. The report excerpts also indicate exposure to Israel-specific geopolitical risk and reliance on external third parties for trials and studies.

- Headquartered in Rehovot, Israel
- Listed on Nasdaq and the Tel Aviv Stock Exchange
- R&D and corporate functions are centered in Israel
- Commercial programs are global through partner relationships
- Israel-based operations create geopolitical exposure

## Strategy

Evogene’s strategy is to commercialize its generative AI chemistry platform through internal product development and strategic partnerships. The company focuses on turning computational molecule design into differentiated candidates with a higher probability of development success, especially in agricultural and pharmaceutical applications. Maintaining market access and listed status also remains important because it supports financing, visibility, and partner credibility.

- **Commercialize ChemPass AI through partnerships** (short-term) — Partnerships help convert the platform into near-term program value and external validation.
- **Advance crop-protection discovery assets** (medium-term) — Agrochemical candidates are the clearest route to product-level value creation.
- **Broaden platform use across pharma and ag** (medium-term) — Multiple end markets can diversify revenue opportunities and improve platform economics.

- Use ChemPass AI to generate differentiated small molecules
- Advance both internal programs and partner-led projects
- Target crop-protection opportunities with commercial potential
- Pursue pharmaceutical discovery applications alongside agtech
- Preserve Nasdaq and TASE listing access to support execution

## Risks

Evogene’s business depends on successful third-party execution, technical validation, and partner adoption of its discovery platform. The company also faces capital-market and listing risk, since Nasdaq compliance and access to financing can affect its ability to fund development programs. As an Israel-based company, it is additionally exposed to regional geopolitical instability and to the inherent uncertainty of R&D-heavy agricultural and pharmaceutical discovery.

- **Nasdaq listing compliance** [high] — The company disclosed efforts to regain compliance with the minimum bid price requirement.
- **Third-party execution failure** [high] — Field trials and pre-clinical studies are performed by third parties, creating schedule and quality risk.
- **Geopolitical disruption in Israel** [high] — The company cited the war involving Israel and Iran/Hezbollah as a risk factor.
- **R&D and commercialization failure** [high] — Discovery-stage molecules may not prove effective, safe, or partnerable.

- Nasdaq minimum bid price compliance risk
- Dependence on third parties for field trials and pre-clinical studies
- Geopolitical exposure tied to Israel-based operations
- R&D programs may fail to reach commercial milestones
- Partnering model depends on external adoption and validation

## Accounting

Evogene’s reported results can be affected by the valuation of warrants, prefunded warrants, and related financing instruments, which can create large non-operating swings. The company also presents discontinued operations tied to the Lavie Bio sale, so investors need to separate core continuing activities from divested businesses. Lease accounting, government grants, and the accounting for deferred revenues and advances also matter because they affect how cash use, support funding, and partner receipts appear in the financial statements.

- **Warrant fair value accounting** — Non-cash volatility in financing line items
- **Discontinued operations** — Improves comparability of continuing operations
- **Deferred revenues and advances** — Revenue timing and balance-sheet contract liabilities
- **Government grants** — Other liabilities and income statement presentation

- Warrants and prefunded warrants create fair-value remeasurement volatility
- Discontinued operations reflect the Lavie Bio asset sale and related run-off
- Government grants affect liabilities and support-related balances
- Deferred revenues and advances affect partner-related timing of revenue
- Lease accounting affects reported liabilities and right-of-use assets

---

*Last updated: 2026-09-28T12:03:35.159096+00:00*